DWTX
Income statement / Annual
Last year (2024), Dogwood Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Dogwood Therapeutics, Inc.'s net income was -$12.35 M.
See Dogwood Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$3.53 M
|
$1.73 M
|
$8.07 M
|
$10.80 M
|
$194.01 K
|
$800.62 K
|
$854.11 K
|
| General & Administrative Expenses |
$8.70 M
|
$3.72 M
|
$4.25 M
|
$4.85 M
|
$9.81 M
|
$1.38 M
|
$1.11 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.70 M
|
$3.72 M
|
$4.25 M
|
$4.85 M
|
$9.81 M
|
$1.38 M
|
$1.11 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$12.23 M
|
$5.45 M
|
$12.32 M
|
$15.64 M
|
$10.01 M
|
$2.18 M
|
$1.96 M
|
| Cost And Expenses |
$12.23 M
|
$5.45 M
|
$12.32 M
|
$15.64 M
|
$10.01 M
|
$2.18 M
|
$1.96 M
|
| Interest Income |
$0.00
|
$150.90 K
|
$67.48 K
|
$5.67 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$92.19 K
|
$0.00
|
$0.00
|
$0.00
|
$384.22 K
|
$295.13 K
|
$152.10 K
|
| Depreciation & Amortization |
$12.18 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
-$12.25 M |
-$5.45 M |
-$12.32 M |
-$15.64 M |
-$10.01 M |
-$2.18 M |
-$1.96 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$122.98 K
|
$150.90 K
|
$67.48 K
|
-$319.33 K
|
-$341.00 K
|
-$295.13 K
|
-$152.10 K
|
| Income Before Tax |
-$12.35 M
|
-$5.30 M
|
-$12.25 M
|
-$15.96 M
|
-$10.35 M
|
-$2.47 M
|
-$2.11 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$503.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$12.35 M
|
-$5.30 M
|
-$12.25 M
|
-$15.96 M
|
-$10.35 M
|
-$2.47 M
|
-$2.11 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-9.42 |
-7.05 |
-27.66 |
-47.9 |
-52.5 |
-12.8 |
-10.93 |
| EPS Diluted |
-9.42 |
-7.05 |
-27.66 |
-47.9 |
-52.5 |
-12.8 |
-10.93 |
| Weighted Average Shares Out |
$1.03 M
|
$751.07 K
|
$442.80 K
|
$333.17 K
|
$197.08 K
|
$193.30 K
|
$193.30 K
|
| Weighted Average Shares Out Diluted |
$1.03 M
|
$751.07 K
|
$442.80 K
|
$333.17 K
|
$197.08 K
|
$193.30 K
|
$193.30 K
|
| Link |
|
|
|
|
|
|
|
